Fred Hutchinson Cancer Research Center

University of Washington Cancer Consortium / SCCA

Seattle, WA

Accepting patients

PTSD Mobile App

PTSD Mobile App for Cancer Survivors
Learn more
  • Observational Trial

Accepting patients

APG-115

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
Learn more
  • MDM2 Inhibitor
  • Phase 1/2

Accepting patients

Treosulfan vs. Clofarabine-Based Conditioning

A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Learn more
  • Allogeneic Stem Cell Transplant
  • Antimetabolites
  • Phase 2

Not currently accepting

211At-BC8-B10

A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 1/2

Accepting patients

Infusion of Expanded Cord Blood Cells

Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Learn more
  • Cord Blood
  • Phase 2

Accepting patients

CLAG-M or FLAG-Ida Chemotherapy

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study
Learn more
  • Allogeneic Stem Cell Transplant
  • White Blood Cell Stimulant
  • Phase 1

Accepting patients

Graft Versus Host Disease-Reduction Strategies

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

RAFA

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

ASTX030

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn more
  • DNMT1 Inhibitor
  • Phase 2/3

Accepting patients

Decitabine Plus a JAK-Inhibitor

A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
Learn more
  • Hypomethylating Agents (HMA)
  • JAK1 Inhibitor
  • JAK2 Inhibitor
  • Phase 2